Early massive accumulation of in-111 pentetreotide in a metastatic liver tumor of islet cell carcinoma

Annals of Nuclear Medicine

Volumn 10, Issue 3, 1996, Pages 339-342

  Tsukamoto, Eriko ^a   Kanegae, Kakuko ^a   Itoh, Kazuo ^a   Okushiba, Shunichi ^a   Ohno, Kohichi ^a   Katoh, Hiroyuki ^a   Tamaki, Nagara ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

gastrin; In 111 pentetreotide; neuroendocrine tumor; somatostatin

Indexed keywords

GALLIUM CITRATE GA 67; PENTETREOTIDE IN 111; SOMATOSTATIN RECEPTOR;

ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HUMAN; LIVER METASTASIS; LIVER SCINTISCANNING; PANCREAS ISLET CELL TUMOR; PRIORITY JOURNAL;

EID: 0029796423     PISSN: 09147187     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03164742     Document Type: Article

References (17)

1. Lamberts SWJ, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 12: 450-482, 1991.
2. 111In-DTPA-D-Phe]-octreotide for detection of somatostatin receptor-positive tumors in rats. Life Sci 49: 1593-1601, 1991.
3. Forsell-Arosson E, Sjalling M, Nilsson O, Tisell LE, Wangberg B, Ahlman H. Indium-111 activity concentration in tissue samples after intravenous injection of Indium-111-DTPA-D-phe-1-octreotide. J Nucl Med 36: 7-12, 1995.
4. Reubi JC, Waser B, Horinberger U, Krenning E, Lamberts SWJ, Gebbers J-O, et al. In vitro autographic and in vivo scintigraphic localization of somatostatin receptors in human lymphatic tissue. Blood 82: 2143-2151, 1993.
5. 123I-Tyr]-octreotide; the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20: 716-731, 1993.
6. Scherubl H, Bader M, Fett U, Hamm B, Schimidt-Gayk H, Koppenhagen K, et al. Somatostatin-receptor imaging of neuroendocrine gastroenteropancreatic tumors. Gastroenterology 105: 1705-1709, 1993.
7. Jamar F, Fiasse R, Leners N, Pauwels S. Somatostatin receptor imaging with Indium-111-pentetreotide in gastroenteropancreatic neuroendocrine tumors: Safety, efficacy and impact on patient management. J Nucl Med 36: 542-549, 1995.
8. Weinel RJ, Neuhaus C, Stapp J, Klotter H-J, Trautmann M-E, Joseph K, et al. Preoperative localization of gastrointestinal endocrine tumors using somatostatin-receptor scintigraphy. Ann Surg 218: 640-645, 1993.
9. Camaille B, Nocaudie M, Pattou F, Huglo D, Deveaux M, Marchandise X, et al. Scintiscans and carcinoid tumors. Surgery 116: 1118-1122, 1994.
10. 111In-DTPA-D-Phe1]-octreotide. Acta Oncologica 3:. 783-786, 1993.
11. Lee JD, Kim DI, Lee JT, Chang JW, Park CY. Indium-111-pentetreotide imaging in intra-axial brain tumors: comparison with thallium-201 SPECT and MRI. J Nucl Med 36: 537-541, 1995.
12. Tenenbaum F, Lumbroso J, Schlumberger M, Mure A, Plouin PP, Caillou B, et al. Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma. J Nucl Med 36: 1-6, 1995.
13. van Ejick CHJ, Krenning EP, Bootsma A, Oei HY, Pel RV, Lindemans J, et al. Somatostatin-receptor scintigraphy in primary breast cancer. The Lancet 343: 640-643, 1994.
14. Lipp RW, Silly H, Ranner G, Dobnig H, Passath A, Leb G, et al. Radiolabeled octreotide for the demonstration of somatostatin receptors in malignant lymphoma and lymphoadenopathy. J Nucl Med 36: 13-18, 1995.
15. 111In-pentetreotide for endocrine gastroenteropancreatic tumors. Harm Metab Res 27 (Suppl): 28-35, 1993.
16. 111In-octreotide scintigraphy in oncology. Metabolism 41: 83-86, 1992.
17. Bajc M, Ingvar C, Persson B, Tibblin S, Karlsson S-E, Edenbrandt L, et al. Dynamic octreotide scintigraphy in neuroendocrine tumors. Acta Radiol 36: 474-477, 1995.